This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HTGM HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About HTG Molecular Diagnostics Stock (NASDAQ:HTGM) 30 days 90 days 365 days Advanced Chart Get HTGM alerts:Sign Up Key Stats Today's Range N/A50-Day Range$5.01▼$6.8052-Week Range N/AVolume773,040 shsAverage Volume294,806 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ. Read More Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HTGM Stock News HeadlinesHTGMQ HTG Molecular Diagnostics, Inc.March 30, 2024 | seekingalpha.comHTG Molecular Diagnostics Inc HTGMQJanuary 4, 2024 | morningstar.comM“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.September 1 at 2:00 AM | InvestorPlace (Ad)HTG Molecular Diagnostics Inc (HTGMQ)September 26, 2023 | uk.investing.comMolecular Diagnostics Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key PlayersAugust 26, 2023 | benzinga.comHTG Molecular stock tanks in wake of Chapter 11 bankruptcy filingJune 6, 2023 | msn.comWhy Are HTG Molecular Diagnostics Shares Plunging TodayJune 6, 2023 | finance.yahoo.comWhy Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?June 6, 2023 | investorplace.comSee More Headlines HTGM Stock Analysis - Frequently Asked Questions How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). The medical research company had revenue of $2.52 million for the quarter, compared to analysts' expectations of $2.90 million. HTG Molecular Diagnostics had a positive trailing twelve-month return on equity of 45.52% and a negative net margin of 324.25%. When did HTG Molecular Diagnostics IPO? HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HTG Molecular Diagnostics investors own include Sangamo Therapeutics (SGMO), Idera Pharmaceuticals (IDRA), NightHawk Biosciences (NHWK), Abeona Therapeutics (ABEO), Exelixis (EXEL), Bionano Genomics (BNGO) and Adamis Pharmaceuticals (ADMP). Company Calendar Last Earnings11/10/2021Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:HTGM CIK1169987 Webwww.htgmolecular.com Phone(520) 547-2827Fax520-547-2837Employees84Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.59 million Net Margins-324.25% Pretax Margin-324.05% Return on Equity45.52% Return on Assets8.93% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.30 Sales & Book Value Annual Sales$6.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / BookN/AMiscellaneous Outstanding Shares2,210,000Free Float2,156,000Market CapN/A OptionableOptionable Beta0.99 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:HTGM) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HTG Molecular Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HTG Molecular Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.